Abstract:Matrix Gla protein (MGP) is a small secreted protein and requires vitamin K dependent γ-carboxylation for its function. MGP has been identified as a local inhibitor of vascular calcification because MGP-deficient mice die due to severe arterial calcification and resulting arterial rupture. Clinical trials revealed that reduction in active MGP predicts poor prognosis in patients due to cardiovascular complications. However, recent studies showed that MGP controls angiogenesis during development. MGP-deficient mice demonstrated abnormal hypervascularization and arteriovenous malformations in kidneys and other organs. This abnormal angiogenesis is largely caused by excessive expression of vascular endothelial growth factor-A (VEGF-A) and VEGF receptor-2 (VEGFR2). However, only a few studies have investigated the roles of MGP in tissue injury. We observed mesangial cell proliferation and mild interstitial fibrosis in addition to increased capillaries in kidneys of MGP-null mice even without injury. We also created a mouse model with kidney injury and found that kidney damage greatly increases MGP expression in peritubular capillary endothelial cells and tubular epithelial cells. Finally, our study showed that impairment of MGP expression aggravates peritubular capillary rarefaction and accumulation of collagen-producing myofibroblasts following kidney injury. Peritubular capillary damage induces capillary loss as well as trans-differentiation of vascular pericytes into myofibroblasts. These results indicate that MGP has the vascular protective effect in the injured kidney. Clinical trials have already started to test the efficacy of MGP activation to repair vascular calcification in patients with chronic kidney diseases. In this "Hypothesis and Theory" article, we discuss possible mechanisms by which MGP protects against vascular damage during tissue injury based on our experimental results and previous results from other research groups.

Unexpected Role of Matrix Gla Protein in Osteoclasts: Inhibiting Osteoclast Differentiation and Bone Resorption.

Gα13 Negatively Controls Osteoclastogenesis Through Inhibition of the Akt-GSK3β-NFATc1 Signalling Pathway

Microfibril-Associated Glycoprotein-1, an Extracellular Matrix Regulator of Bone Remodeling

Downregulation of Mir-223 and Mir-19A Induces Differentiation and Promotes Recruitment of Osteoclast Cells in Giant-Cell Tumor of the Bone Via the Runx2/TWIST-RANK/RANKL Pathway

Oophorectomy‐induced Bone Loss is Attenuated in MAGP1‐deficient Mice

The vascular protective effect of matrix Gla protein during kidney injury

RhoA Promotes Osteoclastogenesis and Regulates Bone Remodeling Through Mtor-Nfatc1 Signaling.

PGC1β Organizes the Osteoclast Cytoskeleton by Mitochondrial Biogenesis and Activation

Microphthalmia transcription factor regulates the expression of the novel osteoclast factor GPNMB

Gsα Controls Cortical Bone Quality by Regulating Osteoclast Differentiation via cAMP/PKA and β-Catenin Pathways

G-protein Gα13 functions as a cytoskeletal and mitochondrial regulator to restrain osteoclast function

Matrix Gla Protein Regulates Adipogenesis and is Serum Marker of Visceral Adiposity

MiR-126-5p Regulates Osteoclast Differentiation and Bone Resorption in Giant Cell Tumor Through Inhibition of MMP-13

HBP/O-GlcNAcylation Metabolic Axis Regulates Bone Resorption Outcome

Osteoblastic Molecular Scaffold Gab1 Is Required For Maintaining Bone Homeostasis

Osteoprotegerin Influences The Bone Resorption Activity Of Osteoclasts

Inhibiting Monoacylglycerol Lipase Suppresses RANKL-Induced Osteoclastogenesis and Alleviates Ovariectomy-Induced Bone Loss

Local Production of Osteoprotegerin by Osteoblasts Suppresses Bone Resorption

Loss of Nmp4 optimizes osteogenic metabolism and secretion to enhance bone quality.

MAGED1 is a Negative Regulator of Bone Remodeling in Mice

Gasdermin D Maintains Bone Mass by Rewiring the Endo-Lysosomal Pathway of Osteoclastic Bone Resorption.